Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback